Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12861011 | 1.00 | FAAH (0.34) | FAAHMGLLRAB9ANLRP3ALDH1A1 | |
| SCHEMBL1154365 | 1.00 | FAAH (0.34) | FAAHMGLLRAB9ANLRP3ALDH1A1 | |
| SCHEMBL1154529 | 0.72 | FAAH (0.35) | FAAHMGLLRAB9ANLRP3ALDH1A1 | |
| SCHEMBL1155194 | 0.72 | FAAH (0.35) | FAAHMGLLRAB9ANLRP3ALDH1A1 | |
| SCHEMBL1154728 | 0.66 | GPR119 (0.34) | FAAHMGLLNLRP3 | |
| SCHEMBL1154699 | 0.64 | GAA (0.34) | ALDH1A1MAPTHTTSMN1; SMN2EGLN3 | |
| SCHEMBL1155093 | 0.64 | GAA (0.34) | ALDH1A1MAPTHTTSMN1; SMN2EGLN3 | |
| SCHEMBL1154701 | 0.64 | GAA (0.34) | ALDH1A1MAPTHTTSMN1; SMN2EGLN3 | |
| SCHEMBL3898117 | 0.64 | DRD2 (0.46) | — | |
| Trifluoroacetic Acid SCHEMBL3895341 | 0.62 | EGLN3 (0.37) | HSP90AA1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893103-B2 | Dipeptidyl peptidase IV (DPP-IV); industrial scale process of making antidiabetics such as (2S,4S)-1-{2-[(3SR,1RS)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-4-fluoro-pyrrolidine-2-carbonitrile starting from ethyl glyoxalate and 3-(1H-1,2,4-triazol-1-ylmethyl)cyclopententylamine for example | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | DPP4, DPP7, DPP3 | FAAH 3626/4885MGLL 1181/4885RAB9A 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.